IN2013MN00567A - - Google Patents

Info

Publication number
IN2013MN00567A
IN2013MN00567A IN567MUN2013A IN2013MN00567A IN 2013MN00567 A IN2013MN00567 A IN 2013MN00567A IN 567MUN2013 A IN567MUN2013 A IN 567MUN2013A IN 2013MN00567 A IN2013MN00567 A IN 2013MN00567A
Authority
IN
India
Prior art keywords
agonist
inhibitor
kinase inhibitor
product
receptor
Prior art date
Application number
Inventor
Peter Robert Hansen
Svetlana Ivanova
Frank Burkamp
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of IN2013MN00567A publication Critical patent/IN2013MN00567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention provides a pharmaceutical product comprising in combination (1) a named glucocorticosteroid receptor agonist and (2) a ß adrenoreceptor agonist a dual ß adrenoreceptor agonist/M receptor antagonist a muscarinic antagonist a p38 kinase inhibitor a neutrophil elastase inhibitor a phosphodiesterase PDE4 inhibitor an IKK2 kinase inhibitor or a non steroidal glucocorticoid receptor agonist and the use of said product in treating respiratory diseases.
IN567MUN2013 2010-10-07 2011-10-05 IN2013MN00567A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination
PCT/GB2011/051898 WO2012046050A1 (en) 2010-10-07 2011-10-05 Novel combinations

Publications (1)

Publication Number Publication Date
IN2013MN00567A true IN2013MN00567A (en) 2015-10-09

Family

ID=43304217

Family Applications (1)

Application Number Title Priority Date Filing Date
IN567MUN2013 IN2013MN00567A (en) 2010-10-07 2011-10-05

Country Status (14)

Country Link
EP (1) EP2624838A1 (en)
JP (1) JP2013538867A (en)
KR (1) KR20130126595A (en)
CN (1) CN103249418A (en)
AU (1) AU2011311310A1 (en)
BR (1) BR112013008362A2 (en)
CA (1) CA2813684A1 (en)
GB (1) GB201016912D0 (en)
IL (1) IL225312A0 (en)
IN (1) IN2013MN00567A (en)
MX (1) MX2013003816A (en)
RU (1) RU2013115103A (en)
SG (1) SG188575A1 (en)
WO (1) WO2012046050A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027922A (en) * 2013-09-04 2015-03-13 주식회사 대웅제약 Novel antifungal pyridinylhydrazide derivatives
KR101657678B1 (en) * 2013-11-05 2016-09-20 주식회사 대웅제약 Novel compound, method for preparation thereof, and antifungal composition comprising the same
AR106697A1 (en) * 2015-11-16 2018-02-07 Esteve Labor Dr OXADIAZOESPÍRICOS COMPOUNDS FOR THE TREATMENT OF ABUSE AND ADDICTION TO DRUGS
WO2018059537A1 (en) * 2016-09-30 2018-04-05 四川海思科制药有限公司 Diazaspiro[5.5]undecane derivative and use thereof
CN117024499A (en) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 Preparation method of steroid compounds introducing methylene hydroxyl group at 2-position

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (en) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4143413B2 (en) 2001-03-22 2008-09-03 グラクソ グループ リミテッド Formanilide derivatives as β2-adrenergic receptor agonists
SE0102616D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102617D0 (en) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
ES2438985T3 (en) 2001-09-14 2014-01-21 Glaxo Group Limited Inhalation formulation comprising phenetanolamine derivatives for the treatment of respiratory diseases
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
AR040661A1 (en) 2002-07-26 2005-04-13 Theravance Inc CRYSTAL DICHLORHYDRATE OF N- {2 - [- ((R) -2-HYDROXI-2-PHENYLETHYLAMINE) PHENYL] ETIL} - (R) -2 HYDROXY-2- (3-FORMAMIDE-4-HYDROXYPHENYL) ETHYLAMINE, RECEIVER AGONIST BETA 2 ADRENERGIC
EP1556034B1 (en) 2002-10-11 2008-04-16 Pfizer Limited Indole derivatives as beta-2 agonists
ATE390407T1 (en) 2002-10-28 2008-04-15 Glaxo Group Ltd PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
SE0300092D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (en) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
PE20040950A1 (en) 2003-02-14 2005-01-01 Theravance Inc BIPHENYL DERIVATIVES AS AGONISTS OF ß2-ADRENERGIC RECEPTORS AND AS ANTAGONISTS OF MUSCARINAL RECEPTORS
JP4767842B2 (en) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド Diarylmethyl compounds and related compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
DE602004021921D1 (en) 2003-05-28 2009-08-20 Theravance Inc AZABICYCLOALKAN COMPOUNDS AS MUSCARIN RECEPTOR ANTAGONISTS
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
DE102004024453A1 (en) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg New long-acting bronchodilators for the treatment of respiratory diseases
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
BRPI0511695A (en) 2004-06-03 2008-01-08 Theravance Inc (beta) 2 adrenergic receptor agonists diamine
US20060002967A1 (en) 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (en) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド Compounds having β2 adrenergic receptor agonist activity and muscarinic receptor antagonist activity
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060114254A1 (en) 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006066907A1 (en) 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
ES2265276B1 (en) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
RS20080411A (en) 2006-03-20 2009-07-15 Pfizer Limited, Amine derivatives
ES2296516B1 (en) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP2010500318A (en) 2006-08-07 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment of respiratory diseases
UY30552A1 (en) 2006-08-22 2008-03-31 Boehringer Ingelheim Int PHARMACOLOGICAL COMBINATIONS BASED ON SUBSTITUTED DERIVATIVES OF THE N- (5- {2- [1,1-DIMETIL-PROPILAMINO] -1-HIDROXI-METIL} -2-HYDROXI-PHENYL) -METANSULPHONAMIDE AND APPLICATIONS
AP2009004791A0 (en) 2006-10-04 2009-04-30 Pfizer Ltd Sulfonamide derivatives as adrenergic agonists andmuscarinic antagonists
ES2302447B1 (en) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders
SA08280783B1 (en) 2007-01-11 2011-04-24 استرازينيكا ايه بي Pyridopyrimidine Derivatives as PDE4 Inhibitors
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (en) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 .
WO2008106016A2 (en) 2007-02-27 2008-09-04 Metrosol, Inc. Prism spectrometer with moveable detector element and with collimated input light
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
EP2170848B1 (en) 2007-06-27 2014-10-22 AstraZeneca AB Pyrazinone derivatives and their use in the treatment of lung diseases
NZ584160A (en) * 2007-10-04 2011-05-27 Astrazeneca Ab Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
HRP20120968T1 (en) 2008-02-06 2013-01-31 Astrazeneca Ab DATES
EA017627B1 (en) 2008-05-13 2013-01-30 Астразенека Аб Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102088976B (en) 2008-05-13 2012-12-26 阿斯利康(瑞典)有限公司 Medicinal products containing muscarinic receptor antagonists and beta2-adrenoceptor agonists
UY32520A (en) 2009-04-03 2010-10-29 Astrazeneca Ab COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802

Also Published As

Publication number Publication date
CN103249418A (en) 2013-08-14
WO2012046050A1 (en) 2012-04-12
EP2624838A1 (en) 2013-08-14
CA2813684A1 (en) 2012-04-12
RU2013115103A (en) 2014-11-20
GB201016912D0 (en) 2010-11-24
JP2013538867A (en) 2013-10-17
SG188575A1 (en) 2013-04-30
MX2013003816A (en) 2013-05-01
IL225312A0 (en) 2013-06-27
KR20130126595A (en) 2013-11-20
BR112013008362A2 (en) 2016-06-14
AU2011311310A1 (en) 2013-04-11

Similar Documents

Publication Publication Date Title
BR112013008140A2 (en) "imidazotriazinone compounds".
IL207440A (en) Use of an anti-calcitonin gene-related peptide (cgrp) antagonist antibody for the manufacture of a medicament for the prevention and/or treatment of chronic pain and/or symptoms of chronic pain and pharmaceutical compositions and kits comprising the same
MX2009008363A (en) Combination of a muscarinic receptor antagonist and a beta-2-adrenoceptor agonist.
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2813223B8 (en) Metal delivery agents and therapeutic uses of the same
ATE469895T1 (en) CGRP RECEPTOR ANTAGONISTS
MY162895A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
CL2007002017A1 (en) COMPOUNDS DERIVED FROM [4,5 '] - BIPIRIMIDINIL-6,4'-DIAMINE; PHARMACEUTICAL COMPOSITION; AND USE AS AN INHIBITOR OF THE ACTIVITY OF CINASA IN CANCER DE VEJIGA, CANCER CERVICAL AND MIELOMA MULTIPLE.
UY32521A (en) COMBINATION TO USE IN THE TREATMENT OF RESPIRATORY DISEASES
IL193049A0 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the tretment of depression, anxiety, and neurodegenerative disordes
MX2009007944A (en) Compounds and compositions as kinase inhibitors.
IN2012DN02177A (en)
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
CL2011002056A1 (en) Compounds derived from the acid {7 - ([1,2,3] triazol-1-yl) -6,7,8,9-tetrahydropylido [1,2-a] indole-10-yl} -acetic acid, receptor antagonist crth2; pharmaceutical composition that includes it; Useful in the treatment of asthma, allergies, cancer among others.
PL2079446T3 (en) Paliperidone sustained release formulation
HK1206726A1 (en) Imidazotriazinone compounds
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
HK1207304A1 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
IN2013MN00567A (en)
PH12013502497A1 (en) Combination comprising umeclidinium and a corticosteroid
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
IL200375A0 (en) Remedy for chemotherapy-resistant cancer containing hla class-i-recognizing antibody as the active ingredient and use of the same
PL1863476T3 (en) The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use